Valuation: Fate Therapeutics, Inc.

Market Cap 283M 249M 232M 213M 400M 27.16B 405M 2.76B 1.08B 13.41B 1.06B 1.04B 46.36B P/E 2026 *
-2.25x
P/E 2027 * -2.36x
Enterprise Value 283M 249M 232M 213M 400M 27.16B 405M 2.76B 1.08B 13.41B 1.06B 1.04B 46.36B EV / Sales 2026 *
54x
EV / Sales 2027 * 54.1x
Free-Float
98.83%
Yield 2026 *
-
Yield 2027 * -
1 day+0.83%
1 week-13.06%
Current month-10.00%
1 month+15.71%
3 months+85.50%
6 months+85.50%
Current year+147.30%
1 week 2.39
Extreme 2.39
2.82
1 month 2.08
Extreme 2.075
3.23
Current year 0.97
Extreme 0.97
3.23
1 year 0.91
Extreme 0.91
3.23
3 years 0.66
Extreme 0.6611
8.83
5 years 0.66
Extreme 0.6611
97.43
10 years 0.66
Extreme 0.6611
121.16
Manager TitleAgeSince
Chief Executive Officer 49 31/12/2024
Director of Finance/CFO 47 19/10/2025
Chief Operating Officer - 30/06/2021
Director TitleAgeSince
Chairman 78 30/11/2011
Director/Board Member 70 16/03/2014
Director/Board Member 47 30/07/2018
Date Insider Type Main position Quantity % Market Cap.
12/06/26 Free

Director

87,900 0.0754%
12/06/26 Free

Director

87,900 0.0754%
12/06/26 Free

Director

175,800 0.1508%
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%-13.06%+95.97%-40.73% 283M
-0.68%+3.08%+53.11%+72.60% 56.19B
-0.27%+0.35%+40.26%+79.88% 54.83B
+1.97%-1.16%-21.00%-13.25% 23.04B
-2.05%-2.14%+0.75%+413.38% 22.7B
-0.21%-0.62%+20.56%-10.90% 20.23B
-1.10%+1.65%+25.74%-30.44% 17.83B
-0.97%-0.59%+33.12%+550.67% 15.65B
+5.29%+1.70%+185.09%+333.94% 15.24B
+0.79%+0.50%+22.39%+184.74% 14.03B
Average +0.35%-0.52%+45.60%+153.99% 24B
Weighted average by Cap. -0.03%+1.06%+38.66%+137.75%

Financials

2026 *2027 *
Net sales 5.25M 4.61M 4.29M 3.94M 7.4M 503M 7.5M 51.04M 19.93M 248M 19.7M 19.27M 859M 5.24M 4.6M 4.29M 3.94M 7.39M 502M 7.49M 50.93M 19.89M 248M 19.66M 19.23M 857M
Net income -133M -117M -109M -99.69M -187M -12.72B -190M -1.29B -504M -6.28B -498M -487M -21.71B -148M -130M -121M -111M -209M -14.19B -212M -1.44B -562M -7.01B -555M -543M -24.22B
Net Debt - -
Logo Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
Employees
161
Date Price Change Volume
27/07/26 US$2.430 +0.83% 564,084
24/07/26 US$2.410 -4.37% 1,044,435
23/07/26 US$2.520 -2.33% 1,637,234
22/07/26 US$2.580 -8.83% 1,499,137
21/07/26 US$2.830 +1.25% 1,143,679
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2.430USD
Average target price
5.411USD
Spread / Average Target
+122.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FATE Stock